Filtered By:
Drug: Dexamethasone
Therapy: Stem Cell Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 252 results found since Jan 2013.
Connexin 43 gap junction affects survival and drug resistance of multiple myeloma side population cells
J Physiol Pharmacol. 2023 Jun;74(3). doi: 10.26402/jpp.2023.3.10. Epub 2023 Aug 30.ABSTRACTDrug resistance remains a major challenge for multiple myeloma (MM) treatment, and side population (SP) cells may play a key role in this resistance. The function of connexin 43 (Cx43)-mediated gap junction intercellular communication (GJ-IC) in MM cells is poorly understood. Bone marrow mesenchymal stem cells (BMSCs) from different sources were isolated and cultured. SP cells of MM cell line RPMI 8266 were separated by flow cytometry. Real-time reverse transcriptase-polymerase chain reaction and Western blot were used to detect Cx43...
Source: J Physiol Pharmacol - September 3, 2023 Category: Drugs & Pharmacology Authors: Z Wang J X Fu X H Zhang Y Sun X P Ge Source Type: research
Houttuynia cordata Thunb repairs steroid-induced avascular necrosis of the femoral head through regulating NF- κB signaling pathway
In conclusion, our study demonstrated that HCT relieved SANFH, which might be possibly achieved by NF-κB pathway.PMID:37652100 | DOI:10.1016/j.toxicon.2023.107270
Source: Toxicon - August 31, 2023 Category: Toxicology Authors: Yuanyuan Wang Yaqi Zhan Chunxiao Ji Chunlei Shi Jie Han Source Type: research
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
